The Global DNA Damage Response Drugs market is bolstering the market growth owing to emerging cancer patients and discovery antibodies. The global DNA damage response drugs market has the potential to grow at propelling CAGR in the forecast period from 2020-2027. Cells have formed a complex DNA damage response defense mechanism during long-term evolution, which is a crucial way to maintain the stability of the genome. Once the device is defective, it can cause a variety of diseases, including tumors. Therefore, the DNA damage response pathway has also become a new anti-tumor drug target.
Genomic instability is one of the most extensive characteristics of cancer cells, and the DNA damage response (DDR) pathway plays a vital role in genomic stability. The DDR pathway is a complex signaling network, which involves cell DNA repair, apoptosis, and cell cycle regulation. Deficiencies in these repair pathways can result in several different genetic disorders, including cancer.
BRCA is an essential protein responsible for repairing DNA errors in the body. Once the mutation fails, the DNA repair ability will significantly reduce, and the cell will accumulate mutations more easily. The accumulation of mutations makes cells more dependent on another DNA repair protein, PARP, to maintain DNA stability, and PARP inhibitors have become an essential ""cleaner"" to deal with BRCA mutant cancer cells.
Type Overview in the Global DNA Damage Response Drugs Market
Based on the type, the global DNA damage response drugs market bifurcated into PARP inhibitors, Others. The PARP inhibitors segment accounted for the largest share of the market is expected to grow at a bolstering rate during the forecast period from 2020-2027. PARP is polyadenylated diphosphate ribosyl polymerase, which is activated when DNA damage broke. Thereby it helps in recognizing and binding to the location where the DNA broke and further activating and catalyzing the poly ADP ribosylation of receptor proteins.
Application Overview in the Global DNA Damage Response Drugs Market
Based on the Application, the global DNA damage response drugs market attributed to Oncological Stroke. The Oncological segment has the largest market share in the global DNA damage response drugs market. The cellular DNA damage is the reason for causing cancer and DNA damage response drug used to treat the oncological disease. Most of the current therapies targeted to tumor DNA, including radiotherapy and many chemotherapy agents. Moreover, targeted therapy based on inhibiting the DDR pathway in cancers offers a novel therapeutic strategy for patients with tumors lacking specific DDR functions. Many small-molecule compounds are targeting the DDR pathway typically developed for substantial cancer therapy. The poly (ADP-ribose) polymerase (PARP) inhibitor is a kind of DDR inhibitors which exploits the principle of synthetic lethality to kill cancer cells selectively.
Region Overview in the Global DNA Damage Response Drugs Market
Based on geography, the global DNA damage response drugs market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. The North America region will be expecting to witness the highest growth during the forecast period from 2020-2027. It is owing to DNA damage response drugs that were first tested on the mice, and cell functions of mice started retrieving. Thus, the market demand for the DNA damage response drugs will continue to bolster in the future as well.
Global DNA Damage Response Drugs Market: Competitive Landscape
Companies such as 4SC AG, Bristol Myers, ARCAGY/ GINECO GROUP, Squibb, British Columbia Cancer Agency, Genentech, Cambridge University Hospitals NHS Foundation Trust, Georgetown University, German Breast Group, GlaxoSmithKline, Jiangsu Hengrui Medicine, Johnson & Johnson, Jonsson Comprehensive Cancer Center, Karyopharm Therapeutics, KuDOS Pharmaceuticals, National Health Service, National Institutes of Health, Tesaro and others are key players in the global DNA damage response drugs market.
1. Research Strategic Development
1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation
2. Research Methodology
2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation
3. Executive Summary
4. Market Insights
4.1. Economic Factor Analysis
4.1.1. Drivers
4.1.2. Trends
4.1.3. Opportunities
4.1.4. Challenges
4.2. Competitors & Product Analysis
4.3. Regulatory Framework
4.4. Company market share analysis, 2019
4.5. Porter’s Five forces analysis
4.6. New Investment Analysis
4.7. PESTEL Analysis
5. Global DNA Damage Response Drugs Market Overview
5.1. Market Size & Forecast, 2016-2027
5.1.1. Demand
5.1.1.1. By Value (USD Million)
5.2. Market Share & Forecast, 2016-2027
5.2.1. By Type
5.2.1.1. PARP Inhibitors
5.2.1.2. Other
5.2.2. By Application
5.2.2.1. Oncological
5.2.2.2. Stroke
5.2.3. By Region
5.2.3.1. Europe
5.2.3.2. North America
5.2.3.3. Asia Pacific
5.2.3.4. South America
5.2.3.5. Middle East & Africa
6. Europe DNA Damage Response Drugs Market Overview
6.1. Europe DNA Damage Response Drugs Size & Forecast, 2016-2027
6.1.1. Demand
6.1.1.1. By Value (USD Million)
6.2. Europe DNA Damage Response Drugs Market Share & Forecast, 2016-2027
6.2.1. By Type
6.2.1.1. PARP Inhibitors
6.2.1.2. Other
6.2.2. By Application
6.2.2.1. Oncological
6.2.2.2. Stroke
6.2.3. By Country
6.2.3.1. Germany
6.2.3.2. UK
6.2.3.3. France
6.2.3.4. Italy
6.2.3.5. Rest of Europe
6.2.4. Company Market Share (Top 3-5)
6.2.5. Economic Impact Study on Europe DNA Damage Response Drugs Market
7. North America DNA Damage Response Drugs Market Overview
7.1. North America DNA Damage Response Drugs Market Size & Forecast, 2016-2027
7.1.1. Demand
7.1.1.1. By Value (USD Million)
7.2. North America DNA Damage Response Drugs Market Share & Forecast, 2016-2027
7.2.1. By Type
7.2.1.1. PARP Inhibitors
7.2.1.2. Other
7.2.2. By Application
7.2.2.1. Oncological
7.2.2.2. Stroke
7.2.3. By Country
7.2.3.1. US
7.2.3.2. Canada
7.2.3.3. Mexico
7.2.4. Company Market Share (Top 3-5)
7.2.5. Economic Impact Study on North America DNA Damage Response Drugs Market
8. Asia Pacific DNA Damage Response Drugs Overview
8.1. Asia Pacific DNA Damage Response Drugs Market Size & Forecast, 2016-2027
8.1.1. Demand
8.1.1.1. By Value (USD Million)
8.2. Asia Pacific DNA Damage Response Drugs Market Share & Forecast, 2016-2027
8.2.1. By Type
8.2.1.1. PARP Inhibitors
8.2.1.2. Other
8.2.2. By Application
8.2.2.1. Oncological
8.2.2.2. Stroke
8.2.3. By Country
8.2.3.1. China
8.2.3.2. India
8.2.3.3. Japan
8.2.3.4. Australia
8.2.3.5. Rest of Asia Pacific
8.2.4. Company Market Share (Top 3-5)
8.2.5. Economic Impact Study on Asia Pacific DNA Damage Response Drugs Market
9. South America DNA Damage Response Drugs Market Overview
9.1. South America DNA Damage Response Drugs Market Size & Forecast, 2016-2027
9.1.1. Demand
9.1.1.1. By Value (USD Million)
9.2. South America DNA Damage Response Drugs Market Share & Forecast, 2016-2027
9.2.1. By Type
9.2.1.1. PARP Inhibitors
9.2.1.2. Other
9.2.2. By Application
9.2.2.1. Oncological
9.2.2.2. Stroke
9.2.3. By Country
9.2.3.1. Brazil
9.2.3.2. Argentina
9.2.3.3. Rest of South America
9.2.4. Company Market Share (Top 3-5)
9.2.5. Economic Impact Study on South America DNA Damage Response Drugs Market
10. Middle East & Africa DNA Damage Response Drugs Market Overview
10.1. Middle East & Africa DNA Damage Response Drugs Market Size & Forecast, 2016-2027
10.1.1. Demand
10.1.1.1. By Value (USD Million)
10.2. Middle East & Africa DNA Damage Response Drugs Market Share & Forecast, 2016-2027
10.2.1. By Type
10.2.1.1. PARP Inhibitors
10.2.1.2. Other
10.2.2. By Application
10.2.2.1. Oncological
10.2.2.2. Stroke
10.2.3. By Country
10.2.3.1. Saudi Arabia
10.2.3.2. UAE
10.2.3.3. South Africa
10.2.3.4. Rest of Middle East & Africa
10.2.4. Company Market Share (Top 3-5)
10.2.5. Economic Impact Study on Middle East & Africa DNA Damage Response Drugs Market
11. Competitor Analysis
11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profile
11.7.1.1. 4SC AG
11.7.1.2. ARCAGY/ GINECO GROUP
11.7.1.3. Bristol Myers Squibb
11.7.1.4. British Columbia Cancer Agency
11.7.1.5. Cambridge University Hospitals NHS Foundation Trust
11.7.1.6. Genentech
11.7.1.7. Georgetown University
11.7.1.8. German Breast Group
11.7.1.9. GlaxoSmithKline
11.7.1.10. Jiangsu Hengrui Medicine
11.7.1.11. Johnson & Johnson
11.7.1.12. Jonsson Comprehensive Cancer Center
11.7.1.13. Karyopharm Therapeutics
11.7.1.14. KuDOS Pharmaceuticals
11.7.1.15. National Health Service
11.7.1.16. National Institutes of Health
11.7.1.17. Tesaro
11.7.1.18. Other players